Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Cash from Operations of 16039000.0 for Q2 2026, down 16.06% year-over-year from 19106885.61 in Q2 2025, and up 14.46% quarter-over-quarter from 18750000.0 in Q1 2026.
Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Cash from Operations for 9 consecutive years, with 16039000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 16.06% year-over-year to 16039000.0; the TTM figure through Jun 2026 stood at 65777000.0 (down 1.34% YoY), while the FY2025 annual figure was 60065000.0, down 2608.07% from the prior year.
- Cash from Operations advanced to 16039000.0 in Q2 2026 per FULC's latest filing, from 18750000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 58899000.0 in Q2 2024 and bottomed at 27882000.0 in Q3 2022.
- Historically, Cash from Operations has averaged 15838166.67 across 5 years, with a median of 19384000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 383.37% — and 2025, when it tumbled 123.46%.
- Fulcrum Therapeutics' Cash from Operations stood at 19696000.0 in 2022, then decreased by 17.58% to 23158000.0 in 2023, then grew by 27.62% to 16761000.0 in 2024, then declined by 0.22% to 16798000.0 in 2025, then climbed by 4.52% to 16039000.0 in 2026.
- Business Quant data shows FULC's Cash from Operations at 16039000.0 in Q2 2026, 18750000.0 in Q1 2026, and 16798000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -16.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.04 Mn |
| Jun 30, 2026 | -16.04 Mn |
| Mar 31, 2026 | -18.75 Mn |
| Mar 31, 2026 | -18.75 Mn |
| Dec 31, 2025 | -16.80 Mn |
| Dec 31, 2025 | -16.80 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Dec 31, 2024 | -16.76 Mn |
| Dec 31, 2024 | -16.76 Mn |
| Sep 30, 2024 | -19.07 Mn |
| Sep 30, 2024 | -19.07 Mn |
| Jun 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 58.90 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Mar 31, 2024 | -25.28 Mn |